Canada - anglais - Health Canada

merck canada inc - recombinant human papillomavirus type 6 l1 protein; recombinant human papillomavirus type 11 l1 protein; recombinant human papillomavirus type 16 l1 protein; recombinant human papillomavirus type 18 l1 protein; recombinant human papillomavirus type 31 l1 protein; recombinant human papillomavirus type 33 l1 protein; recombinant human papillomavirus type 45 l1 protein; recombinant human papillomavirus type 52 l1 protein; recombinant human papillomavirus type 58 l1 protein - suspension - 30mcg; 40mcg; 60mcg; 40mcg; 20mcg; 20mcg; 20mcg; 20mcg; 20mcg - recombinant human papillomavirus type 6 l1 protein 30mcg; recombinant human papillomavirus type 11 l1 protein 40mcg; recombinant human papillomavirus type 16 l1 protein 60mcg; recombinant human papillomavirus type 18 l1 protein 40mcg; recombinant human papillomavirus type 31 l1 protein 20mcg; recombinant human papillomavirus type 33 l1 protein 20mcg; recombinant human papillomavirus type 45 l1 protein 20mcg; recombinant human papillomavirus type 52 l1 protein 20mcg; recombinant human papillomavirus type 58 l1 protein 20mcg - vaccines

États-Unis - anglais - NLM (National Library of Medicine)

merck sharp & dohme llc - human papillomavirus type 6 l1 capsid protein antigen (unii: 61746o90dy) (human papillomavirus type 6 l1 capsid protein antigen - unii:61746o90dy), human papillomavirus type 11 l1 capsid protein antigen (unii: z845vhq61p) (human papillomavirus type 11 l1 capsid protein antigen - unii:z845vhq61p), human papillomavirus type 16 l1 capsid protein antigen (unii: 6lte2dnx63) (human papillomavirus type 16 l1 capsid protein antigen - unii:6lte2dnx63), human papillomavirus type 18 l1 capsid protein antigen (unii: - human papillomavirus type 6 l1 capsid protein antigen 30 ug in 0.5 ml - gardasil® 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: - cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (hpv) types 16, 18, 31, 33, 45, 52, and 58 - genital warts (condyloma acuminata) caused by hpv types 6 and 11 and the following precancerous or dysplastic lesions caused by hpv types 6, 11, 16, 18, 31, 33, 45, 52, and 58: - cervical intraepithelial neoplasia (cin) grade 2/3 and cervical adenocarcinoma in situ (ais) - cervical intraepithelial neoplasia (cin) grade 1 - vulvar intraepithelial neoplasia (vin) grade 2 and grade 3 - vaginal intraepithelial neoplasia (vain) grade 2 and grade 3 - anal intraepithelial neoplasia (ain) grades 1, 2, and 3 gardasil 9 is indicated in boys and men 9 through 45 years of age for the prevention of the following diseases: - anal, oropharyngeal and other head and neck cancers caused by hpv types 16, 18, 31, 33, 45, 52, and 58 - genital war

États-Unis - anglais - NLM (National Library of Medicine)

a-s medication solutions - human papillomavirus type 6 l1 capsid protein antigen (unii: 61746o90dy) (human papillomavirus type 6 l1 capsid protein antigen - unii:61746o90dy), human papillomavirus type 11 l1 capsid protein antigen (unii: z845vhq61p) (human papillomavirus type 11 l1 capsid protein antigen - unii:z845vhq61p), human papillomavirus type 16 l1 capsid protein antigen (unii: 6lte2dnx63) (human papillomavirus type 16 l1 capsid protein antigen - unii:6lte2dnx63), human papillomavirus type 18 l1 capsid protein antigen (unii: - human papillomavirus type 6 l1 capsid protein antigen 30 ug in 0.5 ml - gardasil® 9 is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases: - cervical, vulvar, vaginal, and anal cancer caused by human papillomavirus (hpv) types 16, 18, 31, 33, 45, 52, and 58 - genital warts (condyloma acuminata) caused by hpv types 6 and 11 and the following precancerous or dysplastic lesions caused by hpv types 6, 11, 16, 18, 31, 33, 45, 52, and 58: - cervical intraepithelial neoplasia (cin) grade 2/3 and cervical adenocarcinoma in situ (ais) - cervical intraepithelial neoplasia (cin) grade 1 - vulvar intraepithelial neoplasia (vin) grade 2 and grade 3 - vaginal intraepithelial neoplasia (vain) grade 2 and grade 3 - anal intraepithelial neoplasia (ain) grades 1, 2, and 3 gardasil 9 is indicated in boys and men 9 through 26 years of age for the prevention of the following diseases: - anal cancer caused by hpv types 16, 18, 31, 33, 45, 52, and 58 - genital warts (condyloma acuminata) caused by hpv types 6 and 11 and the following

Singapour - anglais - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - human papillomavirus type 11 l1 protein; human papillomavirus type 16 l1 protein; human papillomavirus type 18 l1 protein; human papillomavirus type 6 l1 protein - solution, sterile - 40 mcg - human papillomavirus type 11 l1 protein 40 mcg; human papillomavirus type 16 l1 protein 40 mcg; human papillomavirus type 18 l1 protein 20 mcg; human papillomavirus type 6 l1 protein 20 mcg

Singapour - anglais - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - human papillomavirus type 11 l1 protein; human papillomavirus type 16 l1 protein; human papillomavirus type 18 l1 protein; human papillomavirus type 6 l1 protein - solution, sterile - 40 mcg - human papillomavirus type 11 l1 protein 40 mcg; human papillomavirus type 16 l1 protein 40 mcg; human papillomavirus type 18 l1 protein 20 mcg; human papillomavirus type 6 l1 protein 20 mcg

Canada - anglais - Health Canada

glaxosmithkline inc - recombinant human papillomavirus type 16 l1 protein; recombinant human papillomavirus type 18 l1 protein - suspension - 20mcg; 20mcg - recombinant human papillomavirus type 16 l1 protein 20mcg; recombinant human papillomavirus type 18 l1 protein 20mcg - vaccines

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - human papillomavirus (hpv) 16 l1 protein 20ug;  ; human papillomavirus (hpv) 18 l1 protein 20ug;   - suspension for injection - active: human papillomavirus (hpv) 16 l1 protein 20ug   human papillomavirus (hpv) 18 l1 protein 20ug   excipient: aluminium hydroxide monobasic sodium phosphate monohydrate monophosphoryl lipid a sodium chloride water for injection - cervarix is indicated in females from 10 to 45 years of age for the prevention of persistent infection, premalignant cervical lesions and cervical cancer caused by oncogenic human papillomavirus (hpv).

Philippines - anglais - FDA (Food And Drug Administration)

n/a; importer: glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - human papillomavirus vaccine [types 16 and 18] (recombinant, adjuvanted, adsorbed) - suspension for injection (im) - formulation: 1 dose (0.5 ml) contains: human papillomavirus type 16 ll protein*...............20 mcg human papillomavirus type 18 l1 protein*... ..........20 mcg *adjuvanted by as04 containing 3-o-desacyl-4-monophosphoryl lipid a (mpl) and aluminum hydroxide, hydrated [al(oh)3]

Philippines - anglais - FDA (Food And Drug Administration)

n/a; importer: glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - human papillomavirus vaccine [types 16 and 18] (recombinant, adjuvanted, adsorbed) - suspension for injection (im) - formulation: 1 dose (0.5 ml) contains: human papillomavirus type 16 ll protein*..............20 mcg human papillomavirus type 18 l1 protein*... ...........20 mcg *adjuvanted by as04 containing 3-o-desacyl-4-monophosphoryl lipid a (mpl) and aluminum hydroxide, hydrated [al(oh)3]

Union européenne - anglais - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily a; neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily b - meningitis, meningococcal - bacterial vaccines, meningococcal vaccines - trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.the use of this vaccine should be in accordance with official recommendations.